The meeting will take place exclusively through an online live webcast. Investors will also vote on equity-plan capacity, authorized common and preferred stock, executive compensation, director elections and future financing-related share issuances. Aethlon (NASDAQ: AEMD) has listed five director candidates for election.
The arrangement gives the company a mechanism to raiseEquityover time, although it is not required to sell shares and any sales remain subject to the agreement’s limits.
Unauthorized access to NovoCure Ltd (NASDAQ: NVCR).'s information systems exposed internal patient ID numbers connected to over 1,400 U.S. patient records. NovoCure said those IDs were used internally and that patient names or other identifying data for those records were not exposed. The company …
ING Groep N.V (OTC: INGVF). Holds a 7.05% beneficial ownership position in Tenax Therapeutics, Inc. (NASDAQ: TENX), equal to 2,639,666 common shares (2.64 million). The ownership statement identifies ING Capital Markets LLC as the entity holding the position and classifies the stake as passive.
Frontier (NASDAQ: ULCC) Airlines, the wholly owned subsidiary, also expects the aircraft changes to maintain similar capacity with fewer aircraft.
The company said theCapitalraise and listing change support its next phase of CuMo project development.
MiniMed Group’s first-quarter net sales rose 16.6% as reported and 15.8% organically to $843 million, with U.S. growth accelerating and international sales continuing to expand. The company raised fiscal 2027 organicRevenuegrowth guidance to approximately 10.5%, while maintaining adjusted EBITDAMarginguidance of approximately 16%.Key HighlightsMiniMed submitted …
Sphera Funds Management Ltd. holds 1,993,496 shares of Tenax Therapeutics, Inc. (NASDAQ: TENX), representing 5.33% of its common stock. The position is reported on a passive basis, with the reporting parties certifying that the securities were not acquired or held to change or influence …
Verekitug Trials Set Broad Enrollment
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) completed its merger with Vertex Pharmaceuticals, converting each eligible share of common stock into the right to receive $85.00 in cash. Crinetics continued as the surviving corporation and became a wholly ownedSubsidiaryof Vertex. The transaction took effect on September …